These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 39070179)

  • 1. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.
    He J; Zeng X; Wang C; Wang E; Li Y
    MedComm (2020); 2024 Aug; 5(8):e671. PubMed ID: 39070179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment.
    Gao X; Bu T; Wang W; Xu Y
    Breast Cancer (Dove Med Press); 2024; 16():621-630. PubMed ID: 39310781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate.
    Subhan MA; Torchilin VP
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
    Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
    Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
    Jiang M; Li Q; Xu B
    Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.
    Gogia P; Ashraf H; Bhasin S; Xu Y
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.
    Medina Pérez VM; Baselga M; Schuhmacher AJ
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.
    Barreca M; Lang N; Tarantelli C; Spriano F; Barraja P; Bertoni F
    Explor Target Antitumor Ther; 2022; 3(6):763-794. PubMed ID: 36654819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates for breast cancer: a bibliometric study and clinical trial analysis.
    Xing M; Li Z; Cui Y; He M; Xing Y; Yang L; Liu Z; Luo L; Wang H; Guo R
    Discov Oncol; 2024 Aug; 15(1):329. PubMed ID: 39093344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
    Shih CH; Lin YH; Luo HL; Sung WW
    Front Pharmacol; 2024; 15():1326296. PubMed ID: 38572425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates in lung cancer: dawn of a new era?
    Coleman N; Yap TA; Heymach JV; Meric-Bernstam F; Le X
    NPJ Precis Oncol; 2023 Jan; 7(1):5. PubMed ID: 36631624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads.
    Monteiro MR; Nunes NCC; Junior AADS; Fêde ABS; Bretas GO; Souza CP; Mano M; da Silva JL
    Breast Cancer (Dove Med Press); 2024; 16():51-70. PubMed ID: 38434801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives.
    Li K; Xie G; Deng X; Zhang Y; Jia Z; Huang Z
    Front Oncol; 2023; 13():1259784. PubMed ID: 38173833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity.
    Dong W; Wang W; Cao C
    ChemMedChem; 2024 Sep; 19(17):e202400109. PubMed ID: 38758596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.